ArticleBMC endocrine disorders2025
Effect of elevated body mass index on glycated albumin levels in healthy individuals.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlycated albumin (GA) is a useful marker for short-term glycemic control, but its levels may be influenced by body composition. Therefore, we aimed to investigate the impact of increasing body mass index (BMI) on GA levels in healthy individuals.
methodsThis cross-sectional study included healthy individuals with normal and elevated BMI. Individuals with diabetes mellitus, pregnancy, acute infection, a history of cardiovascular events, malignancy, chronic liver disease, nephrotic syndrome, thyroid dysfunction, anemia, morbid obesity (BMI ≥ 40 kg/m²), or any other condition known to affect GA levels were excluded. Anthropometric and biochemical measurements were obtained and compared between normal and elevated BMI groups. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) version 22.0.
resultsA total of 52 individuals with elevated BMI and 49 with normal BMI were included in the analysis. Individuals with elevated BMI had significantly lower levels of GA (42.8 ± 7.2 vs. 51.3 ± 6.0, p < 0.001), while levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were markedly higher (0.6 ± 0.4 vs. 0.4 ± 0.2, p < 0.001 and 13.5 ± 12.3 vs. 8.3 ± 7.5, p = 0.002; respectively). BMI showed a moderate inverse association with GA (r=-0.583, p < 0.001). Moreover, BMI was positively associated with CRP (r = 0.366, p < 0.001) and ESR (r = 0.299, p = 0.002). In addition, GA levels exhibited negative correlations with CRP (r=-0.401, p < 0.001) and ESR (r=-0.384, p < 0.001). Multivariate regression analysis confirmed that BMI was independently associated with GA levels (B=-2.727, 95% CI:-5.077 to -0.377, p = 0.024).
conclusionOur results suggest a potential inverse association between BMI and GA levels. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.